Andrew Adamovich, AdvanCell CEO
February 3, 2025 08:58 AM EST
Financing
Startups

Aus­tralian biotech Ad­van­Cell nabs $112M Se­ries C for ra­dio­phar­ma­ceu­ti­cals

Kyle LaHucik

Senior Reporter

Ra­dio­phar­ma­ceu­ti­cals biotech Ad­van­Cell has pulled to­geth­er a $112 mil­lion Se­ries C about two years af­ter its much small­er Se­ries B of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Drug­mak­ers seize on bio­mark­ers to test the FDA's rare dis­ease shift

Up­dat­ed: Drug prices like­ly to soar due to Trump tar­iffs, phar­ma bod­ies warn

Ex­clu­sive: Ger­man biotech de­clares Phase 2 win for non-opi­oid drug for neu­ro­path­ic pain

Irish start­up re­ports mid-stage vic­to­ry for short-act­ing psy­che­del­ic drug in de­pres­sion

Pfiz­er says new col­orec­tal can­cer da­ta could sup­port full ap­proval of Braftovi

J&J’s Ry­bre­vant gets CHMP back­ing weeks af­ter FDA re­jec­tion

A service from the Financial Times